{"version":"1.0","provider_name":"Myanmar News Gazette","provider_url":"https:\/\/myanmarnewsgazette.com","author_name":"admin","author_url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/","title":"Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine - Myanmar News Gazette","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"sv9eJTk7O0\"><a href=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-publication-of-results-from-torchlight-a-randomized-phase-3-trial-of-toripalimab-for-the-treatment-of-metastatic-or-recurrent-triple-negative-breast-cancer-in-nature-medi\/\">Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-publication-of-results-from-torchlight-a-randomized-phase-3-trial-of-toripalimab-for-the-treatment-of-metastatic-or-recurrent-triple-negative-breast-cancer-in-nature-medi\/embed\/#?secret=sv9eJTk7O0\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine&#8221; &#8212; Myanmar News Gazette\" data-secret=\"sv9eJTk7O0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"SHANGHAI, China, Jan. 09, 2024 (GLOBE NEWSWIRE) \u2014 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the publication of results from TORCHLIGHT (NCT04085276), a randomized, double-blind, placebo-controlled phase 3 study comparing the efficacy and safety of [\u2026]","thumbnail_url":"https:\/\/ci5.googleusercontent.com\/proxy\/ZEzmHjzzJUN3Gj951U51kn-Nd1ueU8Zbw1GvdzNZ6kVYyb3MFp52LkITZ2orGNewbR5rDGcbxIUSKVoN5P_BVoXQsQOV2jjuyVzm8JSzr4QzHspxDw7zYlm5oYFCrRr8ch_AW9Wn7Ioi_rrAJBJS373SSUfdAd8jNvOXJ1cS2i9klEqKjxtM2WY9dTYYDQ=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZDc4MTAxOGMtMDAxNy00ZDEwLTg2OTAtYWU2OTkwNDQwZjVkLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png"}